May is completely characterized by intestinal health: first Digestive Disease Week, now World IBD Day. The aim of the IBD action day is to raise awareness about inflammatory bowel diseases [...]
Therapeutic drug monitoring (TDM) is used to measure the concentration of an active ingredient in the patient’s blood. Using this information, physicians can adjust the dose individually to the [...]
So-called TNFα blockers are commonly used in the treatment of inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis. Therapeutic drug monitoring improves the effect of [...]
Chronic inflammatory bowel disease (IBD) is characterized by recurring and often ongoing flares. The most common forms of IBD are Crohns disease and Ulcerative colitis.
Molander et al. investigated if concentrations of fecal calprotectin can be used for predicting relaps after stopping TNFα blocking therapy in patients with Ulcerative Colitis and Morbus Crohn.
Study about first randomized, controlled testing shows that clinical treatment decisions based on therapeutic drug monitoring (TDM) is superior to dose-intensification strategy. One common way of [...]
Ann Gils and her colleagues from KU Leuven evaluated if the biosimilars RemsimaTM and Inflectra® were equally well quantified as Remicade® (Infliximab, IFX) in their clinically validated [...]